回盛生物：预计2025年净利润2.35亿元—2.71亿元 同比扭亏

Core Viewpoint - The company, Ruisong Bio, expects a significant turnaround in its financial performance for 2025, projecting a net profit attributable to shareholders of between 235 million and 271 million yuan, compared to a loss of 20.16 million yuan in the same period last year [1] Group 1: Financial Performance - The projected net profit for 2025 represents a substantial increase compared to the previous year's loss, indicating a strong recovery [1] - The company attributes the expected profit growth to increased operating revenue driven by both domestic and international market expansion [1] Group 2: Operational Factors - Key factors contributing to the profit increase include technological innovation, improved utilization rates of both formulations and active pharmaceutical ingredients, and rising prices of raw materials [1]